<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03521102</url>
  </required_header>
  <id_info>
    <org_study_id>2018-8876</org_study_id>
    <nct_id>NCT03521102</nct_id>
  </id_info>
  <brief_title>Acetaminophen Versus IV Hydromorphone for Pain in the Elderly in the ED</brief_title>
  <official_title>An ED-based Randomized Trial of IV Acetaminophen Versus IV Hydromorphone for Elderly Adults With Acute Severe Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous opioids are the mainstay of acute, severe pain treatment in Emergency Departments&#xD;
      (ED) across the country. Acetaminophen, given orally, has also been used for treatment of&#xD;
      mild to moderate pain. The more potent intravenous (IV) form of acetaminophen has been widely&#xD;
      used in Europe for more than 20 years as post-surgical analgesia and received full FDA&#xD;
      approval in the USA in 2010. As part of a continuing set of studies whose goal is to optimize&#xD;
      treatment of pain among elderly ED patients, this randomized study will compare efficacy and&#xD;
      safety of IV acetaminophen to IV hydromorphone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">March 23, 2022</completion_date>
  <primary_completion_date type="Actual">October 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Verbal pain scale (0-10)</measure>
    <time_frame>60 minutes</time_frame>
    <description>Improvement in 0-10 verbal pain scale between baseline and at 60 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for rescue medication</measure>
    <time_frame>120 minutes</time_frame>
    <description>Requirement of additional analgesic medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>Acetaminophen 1000mg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NRS pain scores will be obtained at 5, 15, 30, 45, 60, 75, 90, 105 and 120 minutes following completion of intervention. Adverse events will be recorded every 15 minutes for the duration of the study protocol. Participants will be reassessed for the need of additional pain control at 60 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydromorphone 0.5mg IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NRS score will be checked at 5 minutes and every 15 minutes for 120 minutes. Adverse events will be recorded every 15 minutes for the duration of the study protocol. The need for additional pain control will be assessed at 60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen 1000mg IV</intervention_name>
    <description>1000mg of IV acetaminophen in 100ml of normal saline, administered as an intravenous drip over 10 minutes + 2ml of normal saline, administered as a slow intravenous push</description>
    <arm_group_label>Acetaminophen 1000mg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone 0.5 mg IV</intervention_name>
    <description>100ml of normal saline, administered as an intravenous drip over 10 minutes, + 0.5mg of IV hydromorphone in 2ml of normal saline, administered as a slow intravenous push</description>
    <arm_group_label>Hydromorphone 0.5mg IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age equal to 65 or greater&#xD;
&#xD;
          2. Pain onset within 7 days with severe pain&#xD;
&#xD;
          3. Has capacity to provide informed consent&#xD;
&#xD;
          4. Understanding English or Spanish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of tramadol or opioids within 7 days&#xD;
&#xD;
          2. Use of acetaminophen or non-steroidal anti-inflammatory medications within 8 hours&#xD;
&#xD;
          3. Chronic pain syndrome: daily pain for &gt; 3 months. Sickle cell anemia, osteoarthritis,&#xD;
             fibromyalgia, and peripheral neuropathies&#xD;
&#xD;
          4. Conditions which may affect acetaminophen or opioid metabolism such as cirrhosis&#xD;
             (Child Pugh A or worse), kidney impairment (CKD 3 or worse), active hepatic disease or&#xD;
             severe dehydration&#xD;
&#xD;
          5. Alcohol intoxication&#xD;
&#xD;
          6. Systolic blood pressure: &lt; 100 mmHg&#xD;
&#xD;
          7. Heart rate: &lt; 60 beats per minute&#xD;
&#xD;
          8. Oxygen saturation: &lt; 95% on room air&#xD;
&#xD;
          9. Use of monoamine oxidase (MAO) inhibitors in the past 30 days&#xD;
&#xD;
         10. Use of transdermal pain patch or oral opioid &gt; 10 days in the prior month&#xD;
&#xD;
         11. Prior enrollment in the same study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Friedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 26, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

